Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic Study on the Impact of Rivastigmine Concerning Genetic Variants of A2M and IL-6 Genes on Iranian Alzheimer's Patients.

Molecular neurobiology - 1 Sept 2016

Zamani Mahdi, Mohammadi Masomeh, Zamani Hamid, Tavasoli Alireza

Abstract excerpt

Alzheimer's disease (AD) is a polygenic and multifactorial disease with a complex inheritance caused by the formation of amyloid plaques and neurofibrillary tangles in the brain. Increasing evidence indicates that many genes including interleukin-6 (IL-6) and alpha 2-macroglobulin (A2M) may contribute to the pathogenesis of AD. The A2M gene encodes α2-macroglobulin which specifically binds with the beta-amyloid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to alpha-Macroglobulins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alzheimer Disease

Share to Cholinesterase Inhibitors

Share to Follow-Up Studies

Share to Interleukin-6

Share to Pharmacogenomic Testing

Source

Identifiers

PMID: 26289409
DOI: 10.1007/s12035-015-9387-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic Study on the Impact of Rivastigmine Concerning Genetic Variants of A2M and IL-6 Genes on Iranian Alzheimer's Patients.PMID 26289409Read ↗

Drug Response of Iranian Alzheimer's Patients to Rivastigmine Concerning Their Genotype for VDR rs11568820 and MTHFR C677T Variants: A Pharmacogenetic and Association Study.Semantic proximity Read ↗

Pharmacogenetic and Association Studies on the Influence of HLA Alleles and Rivastigmine on the Iranian Patients with Late-Onset Alzheimer's Disease.Semantic proximity Read ↗

IL-6-174 G/C and -572 C/G polymorphisms and risk of Alzheimer's disease.Semantic proximity Read ↗

Genetically predicted levels of circulating cytokines and risk of Alzheimer's and Parkinson's disease: evidence from complementary genetic methodsSemantic proximity Read ↗

Pharmacogenomics in Alzheimer's disease.Semantic proximity Read ↗

Alpha 2-Macroglobulin Polymorphisms and Susceptibility to Alzheimer’s Disease: A Comprehensive Meta-Analysis Based on 62 StudiesSemantic proximity Read ↗

Influence of pharmacogenetic factors on Alzheimer's disease therapeutics.Semantic proximity Read ↗

Interleukin-6 -174G/C polymorphism and the risk of Alzheimer's disease in Caucasians: a meta-analysis.Semantic proximity Read ↗

Influence of Alpha-2-Macroglobulin 5 bp I/D and Ile1000Val polymorphisms on the susceptibility of Alzheimer's disease: a systematic review and meta-analysis of 52 studies.Semantic proximity Read ↗

Opportunities in pharmacogenomics for the treatment of Alzheimer’s diseaseSemantic proximity Read ↗

IL-6, IL-8 and IL-10 polymorphisms may impact predisposition of Alzheimer's disease: a meta-analysis.Semantic proximity Read ↗

Genetic polymorphisms of interleukin genes and the risk of Alzheimer's disease: An update meta-analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.